CME Escape Room: Putting Together Clues in HIV, CVD, T2D, and CKD: Escaping Management Mishaps
GET READY TO CHALLENGE YOUR CLINICAL SKILLS WITH THIS UNIQUE AND EDUCATIONAL ESCAPE ROOM ACTIVITY!
Be on the lookout for important clues as you make your way through various patient exam rooms. During the Evaluation, you will be asked to provide specific clues from one of the exam rooms. Participants who provide the correct clues will be entered into a monthly drawing for a $25.00 Amazon e-gift card. Winners will be selected at random on the last business day of the month, until the activity expires on October 18, 2024, and notified via email by Integritas Communications.
Released On
October 18, 2023
Expires On
October 18, 2024
Media Type
Internet
Completion Time
45 minutes
Specialty
Infectious Disease
Topic(s)
Cardiovascular Disease, AIDS/HIV, Diabetes, Sexually Transmitted Diseases, Obesity
This activity is provided by Global Education Group. (ACCME Credit).
This activity is jointly provided by Global Education Group and Integritas Communications. (ANCC Credit)
This activity is supported by an educational grant from Gilead Sciences, Inc.
Credit Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
- Nurses — maximum of 0.75 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The educational design of this activity addresses the needs of US and ex-US infectious disease and HIV specialist physicians, NPs, and PAs involved in the treatment of patients with HIV.
Program Overview
As people with HIV live longer, they can develop common comorbidities affecting aging patients, such as type 2 diabetes (T2D), cardiovascular disease (CVD), and chronic kidney disease (CKD). Further, weight gain may be seen in some patients, though the role of antiretroviral therapy (ART) is still under investigation. Clinicians should become familiar with treatment guidelines, drug-drug interactions, and techniques for shared decision-making to manage aging patients with HIV and common comorbidities. Learners will be guided through this interactive escape room format by Drs. Laura Waters and David Wohl to understand the background of the relationships between T2D, obesity, CVD, and CKD; ART selection for patients with common comorbidities; considerations for use of other medications to manage T2D, CVD, and CKD; and strategies to incorporate trauma-informed care.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the pathophysiologic underpinnings linking CVD, CKD, and T2D in the context of inflammation and HIV
- Tailor therapeutic regimens for aging patients with HIV and multiple comorbidities, such as CVD, CKD, obesity, and/or T2D
- Incorporate trauma-informed care into regular clinical practice
Faculty
Laura J. Waters, MD, FRCP
Consultant Physician, Sexual Heath & HIV
Chair British HIV Association
Mortimer Market Centre
London, United Kingdom
Dr. Laura Waters is an HIV and Sexual Consultant and HIV Lead at the Mortimer Market Centre, London and an Honorary Associate Professor at the Institute of Global Health, University College London. She is the National Specialty Advisor for HIV, chairing the group that advises National Health Service England on HIV treatment, the immediate past chair of the British HIV Association (BHIVA) and Chair of the British Association of Sexual Health and HIV Patient & Public Voice panel.
Dr. Waters has led or co-authored several national guidelines. She has published and presented widely, is a trustee for The Food Chain and previously for the Terrence Higgins Trust. She teaches regularly at local, regional, and national levels, including HIV courses for University College London and the London School of Hygiene and Tropical Medicine. Laura founded The People First Charter in July 2021.
David A. Wohl, MD
Professor of Medicine
Co-Principal Investigator, Global Infectious Disease Clinical Research Unit
Co-Director, Viral Hemorrhagic Fever Clinical Research Group and UNC Project Liberia
Institute for Global Health & Infectious Diseases
The University of North Carolina at Chapel Hill
School of Medicine
Chapel Hill, North Carolina
Dr. David Wohl is a Professor of Medicine in the Division of Infectious Diseases at the University of North Carolina (UNC), as well as Co-Principal Investigator of the Global UNC Infectious Diseases Clinical Trials Unit and Site Leader of its Chapel Hill research site. In addition, he has an active clinical practice at UNC.
Dr. Wohl is a clinical scientist with a focus on emergent infectious diseases. He has spent more than 20 years leading research into the prevention and treatment of HIV and served 2 terms as a member of the US Department of Health and Human Services Antiretroviral Guidelines Panel. Since 2014, he has been working continuously in Liberia, West Africa, conducting research with Ebola survivors to learn about chronic complications and sexual transmission of this infection and establishing the UNC Project Liberia research platform at 2 locations in the country. He and his team have extended this work to examine Lassa fever, a viral hemorrhagic fever endemic in West Africa
In 2020, he helped lead the UNC clinical and research response to COVID-19, directing a large drive-through testing site and 2 COVID-19 vaccination clinics. He served as vice chair of ACTIV-2, an international AIDS Clinical Trials Group/Operation Warp Speed trial of SARS-CoV-2 therapeutics.
Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 0.75 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
- Laura J. Waters, MD, FRCP:
- Consulting Fee: Gilead Sciences, Inc., Merck, Pfizer, Inc.,ViiV
- Contracted Research: Gilead Sciences, Merck, ViiV
- Speakers’ Bureau: ViiV
- David A. Wohl, MD:
- Consulting Fee: Gilead Sciences, Inc., Janssen, Merck, Inc.,ViiV
- Contracted Research: Gilead Sciences, Merck, ViiV
- Honoraria: Gilead Sciences, Inc., Janssen, Merck, ViiV
The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.
Instructions to Receive Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 75% on the posttest, and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There are no fees for this educational activity.
Course Viewing Requirements
System Requirements: PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla
Firefox (v65.0 & above), and Edge (v42.0 & above)
System Requirements: MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or [email protected].